

Claudin 18.2 Targeted Therapy Market: Future Demand and Top Key Players Analysis | 2029

*The Business Research Company's
Claudin 18.2 Targeted Therapy Market:
Future Demand and Top Key Players
Analysis | 2029*

LONDON, GREATER LONDON, UNITED
KINGDOM, October 10, 2025

/EINPresswire.com/ -- "Get 20% Off All
Global Market Reports With Code

ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors



The Business
Research Company

The Business Research Company

What Is The Expected Cagr For The Claudin 18.2 Targeted Therapy Market Through 2029?

The market size of claudin 18.2 targeted therapy has experienced a significant surge in growth

“

Expected to grow to \$3.73
billion in 2029 at a
compound annual growth
rate (CAGR) of 23.6%”

*The Business Research
Company*

recently. The market is projected to expand from \$1.29 billion in 2024 to \$1.60 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 23.9%. The remarkable growth during the historic period is due to various factors including increased research and development efforts, stronger support from government and institutions, a rise in cases of pancreatic cancer, higher investment in healthcare specifically in oncology, and broader global availability of targeted therapies.

The market for claudin 18.2 targeted therapy is anticipated to experience significant expansion in the coming years. By 2029, it's predicted to reach a value of \$3.73 billion, growing at a compound annual growth rate (CAGR) of 23.6%. The surge throughout the forecast timeframe can be credited to various factors such as the increasing approval of cldn18.2-specific therapies, a growing incidence of stomach and gastroesophageal junction (gej) cancers, an expanding range of cldn18.2-focused therapies, rising engagement from pharmaceutical firms, and the growing embrace of personalized medicine. Key trends expected over the forecast period include advances in monoclonal antibody development, breakthroughs in bispecific antibody therapies, progress in antibody-drug conjugates, investment in identifying and validating biomarkers, and research and development investment on combination therapies.

Download a free sample of the claudin 18.2 targeted therapy market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp>

What Are The Key Factors Driving Growth In The Claudin 18.2 Targeted Therapy Market?

The burgeoning number of gastrointestinal cancer cases is anticipated to drive the claudin 18.2 targeted therapy market's expansion in the future. The term "gastrointestinal (GI) cancers" refer to malignant tumors that occur anywhere in the digestive tract, from the esophagus to the rectum. The growth of these cancer types is primarily attributed to unhealthy eating habits that are high on processed foods and low on fiber, thereby increasing gut inflammation and cancer risks. Claudin 18.2 targeted therapy proves effective in treating these cancers by specifically targeting the overexpressed Claudin 18.2 protein on cancer cells. This therapy allows the drugs or antibodies to destroy the cancer cells while sparing the healthy tissues, thereby enhancing the effectiveness of the treatment. For example, the National Library of Medicine, a federal government body in the US, provided data in July 2025 stating that the five gastrointestinal (GI) cancers represented 23.9% of all newly diagnosed cancer cases and 33.2% death rate globally in 2022. They accounted for 4,783,391 fresh cases and 3,235,719 deaths. Thus, the burgeoning gastrointestinal cancer cases are fueling the growth of the Claudin 18.2 targeted therapy market.

What Are The Top Players Operating In The Claudin 18.2 Targeted Therapy Market?

Major players in the Claudin 18.2 Targeted Therapy Global Market Report 2025 include:

- Bristol Myers Squibb Company
- Amgen Inc.
- Astellas Pharma Inc.
- Jiangsu Hengrui Medicine Co. Ltd.
- Shanghai Henlius Biotech Inc.
- Legend Biotech Corporation
- Zai Lab Limited
- Harbour Biomed Ltd.
- CARsgen Therapeutics Holdings Limited
- Genor Biopharma Co. Ltd.

What Are The Key Trends Shaping The Claudin 18.2 Targeted Therapy Industry?

Top companies in the claudin 18.2 targeted therapy segment are honing in on producing ground-breaking solutions like monoclonal antibodies, aiming to improve therapeutic outcomes by selectively engaging with claudin 18.2-expressing cancer cells. Monoclonal antibodies are specially engineered proteins from labs that latch precisely onto one type of target, like a protein found on cancer cells, thereby facilitating the immune system to identify and combat these cells. For example, in March 2024, a permission was granted to Astellas Pharma Inc., a Japan-based drug company, by the Japanese Ministry of Health, Labour and Welfare for the utilisation of VYLOY (zolbetuximab) in treating patients afflicted with CLDN18.2-positive cancer. This targeted treatment for advanced gastric cancer and gastroesophageal junction cancer selectively engages with the CLDN18.2 protein on the cancer cells, stimulating the immune system to eliminate

these cells. Clinical studies indicate that it markedly boosts progression-free and overall survival rates in conjunction with chemotherapy as opposed to chemotherapy solely. This avant-garde therapy offers a viable alternative for patients with HER2-negative, CLDN18.2-positive malignancies, addressing a gap in the aggressive gastric cancer treatment space.

Comprehensive Segment-Wise Insights Into The Claudin 18.2 Targeted Therapy Market
The claudin 18.2 targeted therapy market covered in this report is segmented as

- 1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
- 2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
- 3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
- 4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users

Subsegments:

- 1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
- 2) By Bispecific Antibodies: IgG-Like Bispecific Antibodies, Non-IgG-Like Bispecific Antibodies
- 3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
- 4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors

View the full claudin 18.2 targeted therapy market report:

<https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report>

Global Claudin 18.2 Targeted Therapy Market - Regional Insights

In 2024, the claudin 18.2 targeted therapy market was dominated by the Asia-Pacific region. The global market report for 2025 forecasts this region's growth status. Other regions examined in this report include Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Claudin 18.2 Targeted Therapy Market 2025, By [The Business Research Company](#)

Targeted Therapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report>

Coronavirus Current Therapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report>

Next Generation Antibody Therapeutics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/856653769>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.